Combined treatment with CpG 1585 + 2006 and DLI markedly prolongs the survival of recipients of allogeneic TCD bone marrow challenged with AML cells early (day 17) after BMT.
Lethally irradiated B6 recipients were reconstituted with B10.BR TCD bone marrow (n = 8-10 per group). On day 17, recipients were given C1498 cells (2 × 105). An additional control group received no C1498 cells. Cohorts of mice received no treatment, CpG 1585, CpG 2006, or both ODNs. ODNs treatment were initiated on day 15 and continued through day 43 (A). Other cohorts received DLI (B10.BR splenocytes, 25 × 106/mouse) on day 21 alone or with CpG ODNs (B). (A) As compared with controls, CpG 1585 treatment did not significantly prolong survival (P = .08), whereas CpG 2006 alone or CpG 1585 + 2006 significantly prolonged survival (P = .015 and .001, respectively). (B) As compared with controls, all groups receiving DLI had a significantly prolongation in survival (P ≤ .0006). The inclusion of CpG 1585, 2006, or both ODNs along with DLI resulted in an equivalent or in most cases a significant increase in survival as compared with either DLI alone (P = .01, .004, and .0001, respectively) or the comparable CpG ODN groups alone (P = .001, .10, or .002, respectively).
